Humana (HUM) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 11. On ...

Humana (HUM) shares rallied 3.1% in the last trading session to close at $293.80. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.5% gain over the past four weeks.This marks the fourth consecutive day of Humana’s price increases. Increased optimism related to an uptick in Medicare Advantage plan payments for 2026, which would amount to over $21 billion in additional funds for insurers and favorable earning ...

Talicia is now covered by Humana's Part D Plan, providing access to Talicia for H. pylori therapy to more than eight million additional Medicare lives, without requiring prior therapeutic steps or authorizationThe recently updated American College of Gastroenterology (ACG) Clinical Guideline lists Talicia as a first-line option for treatment of H. pylori infection. Talicia continues to be the most prescribed branded H. pylori therapy by U.S. gastroenterologistsAdditionally, new data describing the foundatio ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Humana (HUM) . This company, which is in the Zacks Medical - HMOs industry, shows potential for another earnings beat.When looking at the last two reports, this health insurer has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 18.85%, on average, in the last two quarters.For the ...

Humana Inc. (HUM) benefits from an extensive Medicaid and Medicare membership base, an aging U.S. population, strategic acquisitions and a strong financial position.Humana’s Zacks Rank & Price PerformanceHumana currently carries a Zacks Rank #3 (Hold).The stock has gained 4.9% in the past three months against the industry’s 5.6% decline. The Zacks Medical sector decreased 11.5% while the S&P 500 composite inched up 0.9% in the same time frame.Image Source: Zacks Investment ResearchHUM’s Favorable Style Scor ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, perhaps no stock market trend is more popular than value investing, which is a strategy that has proven to be successful in all sorts of market environments. Value ...

Group 1 - The healthcare industry is currently facing scrutiny, which has been exacerbated by the murder of a UnitedHealth Group executive [1] - The issues within the healthcare sector have deeper roots than the recent incident, indicating ongoing challenges [1] Group 2 - Crude Value Insights provides an investment service focused on oil and natural gas, emphasizing cash flow and companies with growth potential [1] - Subscribers have access to a stock model account, detailed cash flow analyses of exploration and production firms, and live discussions about the sector [2] - A two-week free trial is available for new subscribers to explore opportunities in the oil and gas market [3]

Shares of Humana Inc (NYSE:HUM) are down 3.7% at $277.38 at last glance, after Cigna Group (NYSE:CI) said it was not pursuing a merger with the smaller health insurance name, and will instead prioritize share buybacks. Cigna stock is on the rise after the news, last seen up 6.7% to trade at $341.04. A Very Ho-Hum Year for HumanaSince the start of the year, Humana stock is underperforming with a 39.4% deficit. The $300 level, which provided support March-April, appears to be moving in as an area of pressure, ...

KEY TAKEAWAYSHumana shares are tumbling Monday morning after The Cigna Group said it is not pursuing a merger with its smaller health insurance rival.Negotiations by Cigna to buy Human fell apart last year but Bloomberg reported last month that the two companies had held informal talks about a deal, with discussions in the early stages.Cigna shares are jumping in premarket trading. Humana (HUM) shares are falling 5% in premarket trading Monday after The Cigna Group (CI) said it is not pursuing a combination ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...